[Form 3] Sarepta Therapeutics,, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Sarepta Therapeutics (SRPT) Form 3 records newly appointed CFO Ryan Ho-Yan Wong’s initial beneficial ownership as of 16 Jul 2025. He directly holds 17,655 common shares. The filing also lists 11 stock-option grants covering 31,031 shares with exercise prices between $67.78 and $155.99 and expirations from 2031-2035; each grant vests 25 % at the first anniversary and then monthly. No shares were bought or sold—this is a baseline disclosure required under Section 16(a). The document contains no operating, financial, or strategic updates and is unlikely to affect the investment thesis for SRPT.

Insights

Securities Analyst

TL;DR: Routine Form 3 discloses CFO’s 17.7k shares and 31k options; informational only, negligible market impact.

The filing establishes Ryan Wong’s insider ownership after assuming the CFO role. The direct stake and sizeable option package align his incentives with shareholders but do not constitute new purchases or sales. Because Form 3s provide historical grant information rather than current transactions, they rarely move the stock. Strike prices largely exceed today’s trading range, so options are currently out-of-the-money, reinforcing a long-term performance focus. Overall impact is neutral.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wong Ryan Ho-Yan

(Last) (First) (Middle)

215 FIRST STREET

(Street)

CAMBRIDGE MA 02140

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/16/2025

3. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	17,655	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	07/31/2022(1)	07/31/2031	Common Stock	9,600	$67.78	D
Stock Option (Right to buy)	03/07/2023(1)	03/07/2032	Common Stock	1,053	$80.42	D
Stock Option (Right to buy)	03/07/2023(1)	03/07/2032	Common Stock	2,558	$80.42	D
Stock Option (Right to buy)	11/30/2023(1)	11/30/2032	Common Stock	1,967	$122.81	D
Stock Option (Right to buy)	11/30/2023(1)	11/30/2032	Common Stock	583	$122.81	D
Stock Option (Right to buy)	03/06/2024(1)	03/06/2033	Common Stock	234	$155.99	D
Stock Option (Right to buy)	03/06/2024(1)	03/06/2033	Common Stock	3,266	$155.99	D
Stock Option (Right to buy)	03/01/2025(1)	03/01/2034	Common Stock	746	$128.67	D
Stock Option (Right to buy)	03/01/2025(1)	03/01/2034	Common Stock	2,954	$128.67	D
Stock Option (Right to buy)	03/10/2026(1)	03/10/2035	Common Stock	6,862	$99.69	D
Stock Option (Right to buy)	03/10/2026(1)	03/10/2035	Common Stock	1,208	$99.69	D

Explanation of Responses:

1. Represents the date upon which the first twenty-five percent of the option granted vests. 1/48th of the total granted option vests and becomes exercisable on each monthly anniversary thereafter.

	/s/ Cristin Rothfuss, as Attorney-in-Fact for Ryan Ho-Yan Wong	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.